دورية أكاديمية
أعرض في EDS

A Case of Long-Term Survival After Glioblastoma, IDH-Wild Type.

التفاصيل البيبلوغرافية
العنوان: A Case of Long-Term Survival After Glioblastoma, IDH-Wild Type.
المؤلفون: Webb LM; Departments of Neurology., Neth BJ; Departments of Neurology., Raghunathan A; Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN., Greipp PT; Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN., Ida CM; Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN., Carabenciov ID; Departments of Neurology., Ruff MW; Departments of Neurology.
المصدر: The neurologist [Neurologist] 2024 Jul 01; Vol. 29 (4), pp. 254-258. Date of Electronic Publication: 2024 Jul 01.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9503763 Publication Model: Electronic Cited Medium: Internet ISSN: 2331-2637 (Electronic) Linking ISSN: 10747931 NLM ISO Abbreviation: Neurologist Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Baltimore, Md : Williams & Wilkins, c1995-
مواضيع طبية MeSH: Glioblastoma*/therapy , Glioblastoma*/diagnostic imaging , Glioblastoma*/pathology , Brain Neoplasms*/pathology, Humans ; Female ; Middle Aged ; Isocitrate Dehydrogenase/genetics ; Fatal Outcome
مستخلص: Introduction: Glioblastoma is a uniformly lethal primary central nervous system neoplasm. Despite the increased understanding of its pathophysiology and treatment advancements, median overall survival for patients with glioblastoma, IDH-wild type remains 14 to 21 months from diagnosis.
Case Report: We present the case of a 48-year-old female who presented with a focal seizure and was found to have a right frontal lobe mass on the brain magnetic resonance imaging. She underwent gross total resection and received a histological diagnosis of glioblastoma. She received radiotherapy and 6 cycles of carmustine (BCNU). Seventeen months later, she developed left hemiparesis. Imaging was concerning for tumor progression, and she was treated with 1 cycle of mechlorethamine, vincristine (oncovin), procarbazine, and prednisone (MOPP). Subsequent surveillance imaging demonstrated a therapeutic response. Twenty-seven years after her glioblastoma diagnosis, she developed status epilepticus and died from respiratory failure. Neuropathology on autopsy demonstrated extensive treatment-related changes but no evidence of recurrent glioblastoma. Genomic testing performed over 30 years after her original diagnosis revealed a profile diagnostic of glioblastoma, IDH-wild type per 2021 World Health Organization criteria.
Conclusions: This patient is one of the longest-known survivors of glioblastoma, IDH-wild type, with pathologic confirmation of glioblastoma at the time of her resection and no evidence of residual disease 26 years after her last treatment. She presented with multiple factors associated with long-term glioblastoma survivorship, including female sex, young age, high Karnofsky score, and multimodal therapy. This case shows that long-term survival after glioblastoma diagnosis is possible and likely mediated through a combination of individual, tumor, and treatment factors.
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Jovčevska I. Genetic secrets of long-term glioblastoma survivors. Bosn J Basic Med Sci. 2019;19:116–124.
Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022;24(Suppl 5):v1–v95.
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306–2316.
Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–1251.
Grossman SA, O’Neill A, Grunnet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003;21:1485–1491.
Caruso R, Pesce A, Wierzbicki V. A very rare case report of long-term survival: a patient operated on in 1994 of glioblastoma multiforme and currently in perfect health. Int J Surg Case Rep. 2017;33:41–43.
Yoshida T, Kawano N, Oka H, et al. Clinical cure of glioblastoma—two case reports. Neurol Med Chir (Tokyo). 2000;40:224–229.
Yamada S, Endo Y, Hirose T, et al. Autopsy findings in a long-term survivor with glioblastoma multiforme—case report. Neurol Med Chir (Tokyo). 1998;38:95–99.
Elvidge AR, Barone BM. Long-term postoperative survival in two cases of glioblastoma multiforme. J Neurosurg. 1965;22:382–386.
Johnson AC. Malignant intracranial tumor: report of three cases with long-term postoperative survival. Surg Neurol. 1981;15:217–219.
Bucy PC, Oberhill HR, Siqueira EB, et al. Cerebral glioblastomas can be cured!. Neurosurgery. 1985;16:714–717.
Sperduto CM, Chakravarti A, Aldape K, et al. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75:1162–1165.
Fukushima S, Narita Y, Miyakita Y, et al. A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy. Neuropathology. 2013;33:576–581.
González Bonet LG, Piqueras-Sánchez C, Roselló-Sastre E, et al. Long-term survival of glioblastoma: a systematic analysis of literature about a case. Neurocirugia (Astur: Engl Ed). 2022;33:227–236.
Rabab’h O, Al-Ramadan A, Shah J, et al. Twenty years after glioblastoma multiforme diagnosis: a case of long-term survival. Cureus. 2021;13:e16061.
Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(Pt 10):2596–2606.
Burgenske DM, Yang J, Decker PA, et al. Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol. 2019;21:1458–1469.
Lié O, Virolle T, Gabut M, et al. SETMAR shorter isoform: a new prognostic factor in glioblastoma. Front Oncol. 2021;11:638397.
Schneider B, Lamp N, Zimpfer A, et al. Comparing tumor microRNA profiles of patients with long‑ and short‑term‑surviving glioblastoma.. Mol Med Rep. 2023;27:8.
Donson AM, Birks DK, Schittone SA, et al. Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. J Immunol. 2012;189:1920–1927.
Das P, Puri T, Jha P, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci. 2011;18:66–70.
Sommerlath VN, Buergy D, Etminan N, et al. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis. Radiat Oncol. 2022;17:15.
Madhugiri VS, Moiyadi AV, Shetty P, et al. Analysis of factors associated with long-term survival in patients with glioblastoma. World Neurosurg. 2021;149:e758–e765.
Kirson ED, Schneiderman RS, Dbalý V, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009;9:1.
Central Nervous System Tumours . 5 ed. WHO classification of tumours. Vol. 6. 2021.
Bai H, Harmanci AS, Erson-Omay EZ, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics. 2016;48:59–66.
Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Acta Neuropathol. 2018;136:805–810.
Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550–563.
Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499–2508.
Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47:458–468.
Brat DJ, Aldape K, Bridge JA, et al. Molecular biomarker testing for the diagnosis of diffuse gliomas. Arch Pathol Lab Med. 2022;146:547–574.
المشرفين على المادة: EC 1.1.1.41 (Isocitrate Dehydrogenase)
تواريخ الأحداث: Date Created: 20240527 Date Completed: 20240705 Latest Revision: 20240705
رمز التحديث: 20240705
DOI: 10.1097/NRL.0000000000000564
PMID: 38797928
قاعدة البيانات: MEDLINE
الوصف
تدمد:2331-2637
DOI:10.1097/NRL.0000000000000564